PMID- 34362349
OWN - NLM
STAT- MEDLINE
DCOM- 20220104
LR  - 20231107
IS  - 1472-6823 (Electronic)
IS  - 1472-6823 (Linking)
VI  - 21
IP  - 1
DP  - 2021 Aug 6
TI  - Correlation of serum delta-like ligand-4 level with the severity of diabetic 
      retinopathy.
PG  - 157
LID - 10.1186/s12902-021-00814-6 [doi]
LID - 157
AB  - BACKGROUND: Diabetic retinopathy (DR) is one of the most serious microvascular 
      complications of type 2 diabetes mellitus (T2DM). Delta-like ligand-4 (DLL4) 
      maintains the normal physiological microenvironment of the retina. However, the 
      relationship between the level of DLL4 and the severity of DR remains unclear. 
      METHODS: We retrospectively analyzed serum DLL4 levels and other laboratory and 
      clinical data in 94 T2DM patients (35 patients without DR [NDR], 32 with 
      non-proliferative DR [NPDR], 27 with proliferative DR [PDR]), and 30 healthy 
      controls. RESULTS: The serum DLL4 level was significantly greater in the NDR 
      group (43.38 +/- 16.23 pg/mL), NPDR group (56.57 +/- 25.89 pg/mL), and PDR group 
      (74.97 +/- 25.28 pg/mL) than in the healthy controls (29.9 +/- 8.92 pg/mL; all 
      p < 0.05). Among T2DM patients, the level of DLL4 increased as the severity of DR 
      increased (p < 0.05). Logistic regression analysis demonstrated that DR was 
      positively associated with DLL4, glycosylated hemoglobin (HbA1c), fasting blood 
      glucose (FBG), and duration of T2DM (all p < 0.05). Consistently, receiver 
      operating characteristic (ROC) curve analysis also indicated that DLL4 was a 
      potential candidate biomarker for identifying the severity of DR. CONCLUSIONS: 
      T2DM patients, especially those with DR, have increased serum levels of DLL4. 
      DLL4 may be used as a biomarker and an independent risk factor for DR, and 
      targeting DLL4 may be a potential therapy in patients with DR.
CI  - (c) 2021. The Author(s).
FAU - Zhu, Yan
AU  - Zhu Y
AD  - Department of Endocrinology, The First Affiliated Hospital of Soochow University, 
      No.188 Shizi Road, Suzhou, China.
FAU - Hu, Jingcheng
AU  - Hu J
AD  - Department of Endocrinology, The First Affiliated Hospital of Soochow University, 
      No.188 Shizi Road, Suzhou, China.
FAU - Du, Xuan
AU  - Du X
AD  - Department of Endocrinology, The First Affiliated Hospital of Soochow University, 
      No.188 Shizi Road, Suzhou, China.
FAU - Fang, Qionglei
AU  - Fang Q
AD  - Department of Endocrinology, The First Affiliated Hospital of Soochow University, 
      No.188 Shizi Road, Suzhou, China.
FAU - Zhou, Yingyi
AU  - Zhou Y
AD  - Department of Endocrinology, The First Affiliated Hospital of Soochow University, 
      No.188 Shizi Road, Suzhou, China. Renee1987@qq.com.
FAU - Chen, Ke
AU  - Chen K
AD  - Department of Endocrinology, The First Affiliated Hospital of Soochow University, 
      No.188 Shizi Road, Suzhou, China. chenkework_1987@163.com.
AD  - Department of Thoracic Surgery, The First Affiliated Hospital of Soochow 
      University, No.188 Shizi Road, Suzhou, China. chenkework_1987@163.com.
LA  - eng
PT  - Journal Article
DEP - 20210806
PL  - England
TA  - BMC Endocr Disord
JT  - BMC endocrine disorders
JID - 101088676
RN  - 0 (Adaptor Proteins, Signal Transducing)
RN  - 0 (Biomarkers)
RN  - 0 (Blood Glucose)
RN  - 0 (Calcium-Binding Proteins)
RN  - 0 (DLL4 protein, human)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (hemoglobin A1c protein, human)
SB  - IM
MH  - Adaptor Proteins, Signal Transducing/*blood
MH  - Biomarkers/*blood
MH  - Blood Glucose/*analysis
MH  - Calcium-Binding Proteins/*blood
MH  - Case-Control Studies
MH  - Diabetes Mellitus, Type 2/*complications
MH  - Diabetic Retinopathy/blood/*diagnosis/etiology
MH  - Female
MH  - Follow-Up Studies
MH  - Glycated Hemoglobin/*analysis
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - ROC Curve
MH  - Retrospective Studies
PMC - PMC8344193
OTO - NOTNLM
OT  - Delta-like ligand-4
OT  - Diabetic retinopathy
OT  - Independent risk factor
OT  - Type 2 diabetes mellitus
COIS- The authors declare that they have no competing interests.
EDAT- 2021/08/08 06:00
MHDA- 2022/01/05 06:00
PMCR- 2021/08/06
CRDT- 2021/08/07 05:26
PHST- 2021/03/22 00:00 [received]
PHST- 2021/07/21 00:00 [accepted]
PHST- 2021/08/07 05:26 [entrez]
PHST- 2021/08/08 06:00 [pubmed]
PHST- 2022/01/05 06:00 [medline]
PHST- 2021/08/06 00:00 [pmc-release]
AID - 10.1186/s12902-021-00814-6 [pii]
AID - 814 [pii]
AID - 10.1186/s12902-021-00814-6 [doi]
PST - epublish
SO  - BMC Endocr Disord. 2021 Aug 6;21(1):157. doi: 10.1186/s12902-021-00814-6.